Q-omics provides the consensus-scored ALG1L7P profile across patient tissues and cancer cell-line models. ALG1L7P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ALG1L7P is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, ALG1L7P RNA expression shows 14,809 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRP, and ACC as cancer lineages where ALG1L7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG1L7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG1L7P survival associations across molecular data types. ALG1L7P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG1L7P RNA expression–survival associations across cancer types. High ALG1L7P expression shows unfavorable associations in LIHC, KIRC, KICH and LUAD, but favorable associations in UVM and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ALG1L7P RNA expression.
This table summarizes ALG1L7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ALG1L7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG1L7P shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRP, LIHC, CHOL and LUAD. The KIRP box plot shows higher ALG1L7P RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with ALG1L7P in patient tissues and cancer cell lines. In patient samples, ALG1L7P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
